vigabatrin
E874312
Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
All labels observed (1)
| Label | Occurrences |
|---|---|
| vigabatrin canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10609989 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: vigabatrin Context triple: [Dravet syndrome, hasContraindicatedDrug, vigabatrin]
-
A.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
B.
phenytoin
Phenytoin is an antiepileptic medication commonly used to prevent and control seizures by stabilizing neuronal activity in the brain.
-
C.
Lyrica
Lyrica is a prescription medication (pregabalin) commonly used to treat nerve pain, fibromyalgia, and certain types of seizures.
-
D.
Symmetrel
Symmetrel is a brand-name antiviral and antiparkinsonian medication whose active ingredient is amantadine.
-
E.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: vigabatrin Target entity description: Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
-
A.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
B.
phenytoin
Phenytoin is an antiepileptic medication commonly used to prevent and control seizures by stabilizing neuronal activity in the brain.
-
C.
Lyrica
Lyrica is a prescription medication (pregabalin) commonly used to treat nerve pain, fibromyalgia, and certain types of seizures.
-
D.
Symmetrel
Symmetrel is a brand-name antiviral and antiparkinsonian medication whose active ingredient is amantadine.
-
E.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
GABAergic drug
ⓘ
anticonvulsant ⓘ antiepileptic drug ⓘ pharmaceutical drug ⓘ |
| actsOn | GABA transaminase NERFINISHED ⓘ |
| administeredAs | oral powder for solution ⓘ |
| affects | visual pathways ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIndication |
infantile spasms in children 1 month to 2 years of age
ⓘ
refractory complex partial seizures in adults ⓘ |
| belongsToClass | succinimide analogs ⓘ |
| chemicalName | (±)-4-amino-5-hexenoic acid ⓘ |
| contraindicatedIn |
hypersensitivity to vigabatrin
ⓘ
patients with pre-existing significant visual field defects ⓘ |
| developedFor | epilepsy treatment ⓘ |
| eliminationRoute | renal excretion ⓘ |
| hasAdverseEffect |
behavioral changes
ⓘ
dizziness ⓘ fatigue ⓘ retinal toxicity ⓘ somnolence ⓘ weight gain ⓘ |
| hasATCCode | N03AG04 ⓘ |
| hasBlackBoxWarning | risk of permanent vision loss ⓘ |
| hasChemicalFormula | C6H11NO2 ⓘ |
| hasEffectOn | increases inhibitory neurotransmission ⓘ |
| hasHalfLife | approximately 5 to 8 hours in adults ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMechanismOfAction | irreversible GABA transaminase inhibitor ⓘ |
| hasPregnancyCategory | may cause fetal harm (risk–benefit assessment required) ⓘ |
| hasRiskManagementProgram | REMS program in the United States NERFINISHED ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
oral solution ⓘ oral tablet ⓘ |
| hasSeriousAdverseEffect |
peripheral visual field constriction
ⓘ
permanent visual field loss ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| increasesLevelOf | gamma-aminobutyric acid in the brain ⓘ |
| isAnalogOf | gamma-aminobutyric acid ⓘ |
| mayCause | MRI signal changes in infants ⓘ |
| notSignificantlyMetabolizedBy | cytochrome P450 enzymes ⓘ |
| requiresMonitoring | periodic visual field testing ⓘ |
| riskIncreasesWith |
higher cumulative dose
ⓘ
longer duration of therapy ⓘ |
| shouldBeUsedWhen | benefits outweigh risk of vision loss ⓘ |
| usedFor |
West syndrome
NERFINISHED
ⓘ
infantile spasms ⓘ refractory partial seizures ⓘ treatment-resistant epilepsy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: vigabatrin Description of subject: Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.